BioXcel Therapeutics (HAM:BX20) Cyclically Adjusted PB Ratio: (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BX20 BioXcel Therapeutics Inc HAM:BX20
9 GF Score
Price €0.19
GF Value €0.47
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioXcel Therapeutics  (HAM:BX20) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BioXcel Therapeutics Cyclically Adjusted PB Ratio Related Terms


BioXcel Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for BioXcel Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics Cyclically Adjusted PB Ratio Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.04

BioXcel Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.04 0.00 0.00

HAM:BX20 vs YCBD, APUS, LVRLF: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioXcel Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Cyclically Adjusted PB Ratio falls into.


HAM:BX20
9GF Score
BioXcel Therapeutics Inc HAM:BX20
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioXcel Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BioXcel Therapeutics's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, BioXcel Therapeutics's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=-3.651/324.0540*324.0540
=-3.651

Current CPI (Dec25) = 324.0540.

BioXcel Therapeutics Annual Data

Book Value per Share CPI Adj_Book
201612 -0.323 241.432 -0.434
201712 -0.875 246.524 -1.150
201812 34.916 251.233 45.037
201912 21.421 256.974 27.013
202012 111.339 260.474 138.516
202112 112.164 278.802 130.369
202212 41.203 296.797 44.987
202312 -27.695 306.746 -29.258
202412 -28.662 315.605 -29.429
202512 -3.651 324.054 -3.651

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BioXcel Therapeutics (HAM:BX20) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be undervalued. The current stock price of €0.19 is trading 60% below its estimated GF Value™ of €0.47. GuruFocus considers BioXcel Therapeutics to be Possible Value Trap.

Key valuation signals for HAM:BX20:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €0.47 vs. price of €0.19 (60% below fair value)
  • GF Score™: 9/100 with 3 warning signs

No single metric tells the full story. See the HAM:BX20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioXcel Therapeutics Business Description

Other Exchanges BTAI:USA
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
9GF Score

Get the complete analysis for HAM:BX20

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€0.47
GF Value